Drug Database · Clinicians

Ibuprofen

Brands (74) Mylan, Profen, Advil…Show all

Nonsteroidal Anti-inflammatory Drug (Cyclooxygenase Inhibitors) US FDA class
Non-steroidal anti-inflammatory drug (NSAID)/Analgesic/Antipyretic; Non-steroidal anti-inflammatory Drug/NSAID (propionic acid derivative); and others PH FDA category

Not recommended in advanced CKDRx · Prescription drugOTC · Over-the-counter103 PH productsPNF-listedPhilHealth GAMOT Kidney dosing reviewed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 17577b3b-e755-45d1-8b53-775d058578b2, version date July 29, 2026 (Ibuprofen · Amneal Pharmaceuticals LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Carefully consider the potential benefits and risks of Ibuprofen Tablets and other treatment options before deciding to use Ibuprofen Tablets.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Carefully consider the potential benefits and risks of Ibuprofen Tablets and other treatment options before deciding to use Ibuprofen Tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see WARNINGS]. Ibuprofen Tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.

Ibuprofen Tablets are indicated for relief of mild to moderate pain. Ibuprofen Tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of Ibuprofen Tablets in children have not been conducted.

Contraindications

  • Hypersensitivity to the drug
  • Asthma, urticaria or allergic-type reaction after aspirin or other NSAIDs
  • Setting of coronary artery bypass graft (CABG) surgery
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS Ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. Ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see WARNINGS, Anaphylactoid Reactions, and PRECAUTIONS, Preexisting Asthma]. In the setting of coronary artery bypass graft (CABG) surgery [see WARNINGS].

Dosing: Adult

  • Mild to moderate pain: 400 mg every 4 to 6 hours as needed (higher single doses no more effective)
  • Dysmenorrhea: 400 mg every 4 hours as needed
  • Rheumatoid arthritis, osteoarthritis: 1,200 to 3,200 mg/day (400, 600 or 800 mg three or four times daily); maximum 3,200 mg/day
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see WARNINGS]. After observing the response to initial therapy with ibuprofen tablets, the dose and frequency should be adjusted to suit an individual patient's needs.

Do not exceed 3200 mg total daily dose. If gastrointestinal complaints occur, administer ibuprofen tablets with meals or milk. Rheumatoid arthritis and osteoarthritis, including flare-ups of chronic disease: Suggested Dosage: 1200 mg to 3200 mg daily (400 mg, 600 mg or 800 mg tid or qid). Individual patients may show a better response to 3200 mg daily, as compared with 2400 mg, although in well-controlled clinical trials patients on 3200 mg did not show a better mean response in terms of efficacy.

Therefore, when treating patients with 3200 mg/day, the physician should observe sufficient increased clinical benefits to offset potential increased risk. The dose should be tailored to each patient, and may be lowered or raised depending on the severity of symptoms either at time of initiating drug therapy or as the patient responds or fails to respond.

In general, patients with rheumatoid arthritis seem to require higher doses of ibuprofen tablets than do patients with osteoarthritis. The smallest dose of ibuprofen tablets that yields acceptable control should be employed. A linear blood level dose-response relationship exists with single doses up to 800 mg [See CLINICAL PHARMACOLOGY for effects of food on rate of absorption].

The availability of three tablet strengths facilitates dosage adjustment. In chronic conditions, a therapeutic response to therapy with ibuprofen tablets is sometimes seen in a few days to a week but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.

Mild to moderate pain: 400 mg every 4 to 6 hours as necessary for relief of pain. In controlled analgesic clinical trials, doses of ibuprofen tablets greater than 400 mg were no more effective than the 400 mg dose. Dysmenorrhea: For the treatment of dysmenorrhea, beginning with the earliest onset of such pain, ibuprofen tablets should be given in a dose of 400 mg every 4 hours as necessary for the relief of pain.

Dosing: Altered kidney function

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) eliminated in urine as inactive metabolites. NSAIDs reduce kidney blood flow and can cause acute kidney injury, especially with diuretics, ACE inhibitors, heart failure, liver disease, older age or existing kidney impairment. The US prescription label does not recommend ibuprofen in advanced renal disease.

Kidney function measure: Label uses 'impaired renal function' and 'advanced renal disease' without a CrCl number. Mapping 'advanced' to CrCl <30 is our judgment.

Show full dosing details
CrCl ≥60 mL/min
Usual: pain 400 mg every 4 to 6 hours as needed; arthritis 1,200 to 3,200 mg/day in 3 or 4 doses; maximum 3,200 mg/day (label). Lowest effective dose, shortest duration.
CrCl 30–59 mL/min
No label dose change. Impaired kidney function is a risk factor for NSAID kidney injury: monitor creatinine, potassium and blood pressure; avoid volume depletion and the ACE inhibitor or ARB plus diuretic combination.
CrCl 15–29 mL/min
Not recommended in advanced renal disease (no controlled data); if it must be started, monitor kidney function closely (label, Warnings: Advanced Renal Disease).
CrCl <15 mL/min (not on dialysis)
Not recommended in advanced renal disease (no controlled data); if it must be started, monitor kidney function closely (label, Warnings: Advanced Renal Disease).
Hemodialysis (intermittent)
Not recommended (advanced renal disease; label). NSAIDs may hasten loss of residual kidney function.
Peritoneal dialysis
Not recommended (advanced renal disease; label). NSAIDs may hasten loss of residual kidney function.
CRRT
Avoid: NSAIDs can worsen acute kidney injury.
  • Dialyzable? Not stated in the label.
  • Monitoring Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, older adults, or with diuretics, ACE inhibitors or ARBs. Gastrointestinal bleeding; hemoglobin with long-term use.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
No kidney dose change; keep the child hydrated. NSAID-associated acute kidney injury occurs in children, mostly after correctly dosed NSAIDs and with dehydration; children under 5 had more severe AKI (Misurac 2013). Avoid during vomiting, diarrhea or poor intake.
eGFR 30–59
Avoid if dehydrated; check serum creatinine with repeated use. NSAID-associated acute kidney injury occurs in children, mostly after correctly dosed NSAIDs and with dehydration; children under 5 had more severe AKI (Misurac 2013). Avoid during vomiting, diarrhea or poor intake.
eGFR 15–29
Avoid: NSAIDs are not recommended in advanced renal disease (label warning, not age-limited; site mapping to eGFR <30). NSAID-associated acute kidney injury occurs in children, mostly after correctly dosed NSAIDs and with dehydration; children under 5 had more severe AKI (Misurac 2013). Avoid during vomiting, diarrhea or poor intake.
eGFR <15 (not on dialysis)
Avoid: NSAIDs are not recommended in advanced renal disease (label warning, not age-limited; site mapping to eGFR <30). NSAID-associated acute kidney injury occurs in children, mostly after correctly dosed NSAIDs and with dehydration; children under 5 had more severe AKI (Misurac 2013). Avoid during vomiting, diarrhea or poor intake.
Hemodialysis (intermittent)
Avoid: advanced kidney disease or acute kidney injury (label warning, not age-limited); NSAIDs can worsen kidney injury.
Peritoneal dialysis
Avoid: advanced kidney disease or acute kidney injury (label warning, not age-limited); NSAIDs can worsen kidney injury.
CRRT
Avoid: advanced kidney disease or acute kidney injury (label warning, not age-limited); NSAIDs can worsen kidney injury.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Dosing: Pediatric

Approved ages
The selected prescription tablet label is not for children; PH registers ibuprofen oral suspensions and drops used for fever and pain in children (separate OTC labeling, not stored).
Usual dose
Not given in this label (pediatric suspensions are OTC products with separate labeling).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness of ibuprofen tablets in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use As with any NSAIDs, caution should be exercised in treating the elderly (65 years and older).

Dosage forms

Philippines

  • Suspension: 40 mg/mL, 100 mg per 5 mL, 100 mg/5 mL, 200 mg/5 mL
  • Tablet: 200 mg, 400 mg
  • Film-coated tablet: 200 mg, 400 mg
  • Softgel capsule: 200 mg, 400 mg
  • Oral suspension: 100 mg/5 mL, 200 mg per 5 mL, 200 mg/5 mL
  • Capsule: 200 mg
  • ) solution for i.v. infusion: 100 mg/mL (400 mg/4 mL
  • Soft gelatin capsule: 400 mg
  • Soft-gelatin capsule: 400 mg
  • Solution for i. v. infusion: 100 mg/mL (800 mg/8 mL

Registered products in the Philippines

103 products registered with the Food and Drug Administration (FDA) Philippines list Ibuprofen as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products103
Philippine FDA-registered products for Ibuprofen
Package insert
AceprofenIbuprofen
400 mg Film-Coated TabletAlu/PVC Foil Blister Pack x 10's (Box of 100's)
Rx
Umedica Laboratories Pvt. Ltd.India
Eon Pharmatek Inc.
DR-XY47467
Oct 19, 2031
AdvilIbuprofen
100 mg/5 mL SuspensionWhite Polypropylene (PP) Plastic Bottle x 60 mL (Box of 1's)
OTC
Interphil Laboratories, Inc.Philippines
Trader: GlaxoSmithKline Consumer Healthcare Philippines, Inc.
DR-XY29056
Oct 15, 2028
AdvilIbuprofen
200 mg Softgel CapsulePVDC/PVC/PE Blister pack x 10's Box of 100's and 10's; Physician sample (Flap by 1's)
OTC
Catalent Pharma Solutions, LLCUSA
Importer: GlaxoSmithKline Consumer Healthcare Philippines Inc.
DR-XY32938
Dec 10, 2027
Advil Children's Pain and Fever ReliefIbuprofen (For Export Only)
100 mg/5 mL SuspensionAmber Glass Bottle with white PP cap (individually boxed with PP double ended measuring spoon) 100 mL and 200 mL
OTC
Interphil Laboratories Inc.Philippines
—
DR-XY36546
Aug 27, 2029
Advil Infant's Pain and Fever Relief (Grape Flavor)Ibuprofen
40 mg/mL SuspensionAmber Bottle with dosing device x 40 mL (Box of 1's)
OTC
Interphil Laboratories, Inc.Philippines
Trader: Pfizer Consumer Healthcare
DR-XY35153 [For export only]
Nov 13, 2028
AlaxproIbuprofen
400 mg TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories, Inc.Philippines
Drugmaker's Laboratories, Inc.
DRP-5635-01
Aug 19, 2028
Anvil 200Ibuprofen
200 mg Softgel CapsuleAluminum foil/PVC film clear blister pack x 10’s (Box of 10’s and 30’s)
OTC
Phil. United Pharma CorporationPhilippines
ATC Healthcare International Corp.
DRP-7504
Nov 23, 2027
Anvil 200Ibuprofen
200mg Film-Coated tabletAlu/PVC Film Clear Blister Pack x 10's )Box of 10's, 20's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
ATC Healthcare International Corp.
DRP-9452
Jan 8, 2031
Anvil 400Ibuprofen
400mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma Corp.Philippines
ATC Healthcare International Corp.
DRP-9451
Jan 8, 2031
Anvil 400Ibuprofen
400mg Softgel CapsuleAluminum foil/PVC film clear blister pack x 10’s (Box of 10’s); Aluminum foil/PVC film clear blister pack x 10’s B(ox of 30’s)
OTC
Phil. United Pharma CorporationPhilippines
ATC HEALTHCARE INTERNATIONAL CORP.
DRP-7503
Nov 23, 2027
AstrofenIbuprofen
100 mg/5 mL Oral Suspension (Orange Flavor)Amber Glass Bottle x 60 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Nurturemed Pharma Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3563-03
Mar 16, 2031
AstrofenIbuprofen
200 mg/5 mL Suspension (Orange Flavor)Amber Glass Bottle x 60 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Nurturemed Pharma Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3562-04
Mar 25, 2031
BrofenIbuprofen
400mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Mercury Laboratories Ltd.India
Philgen Pharmaceuticals Inc.
DRP-12607
Sep 13, 2027
BromedIbuprofen
400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Curis Lifesciences Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-15654
Aug 29, 2029
BufenIbuprofen (Orange Flavor)
100 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-3563
May 28, 2030
BufenIbuprofen
200 mg/5 mL Suspension (Orange Flavor)Amber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-3562
Jun 7, 2030
BufenolIbuprofen (Orange flavor)
100 mg/5 mL Oral SuspensionAmber Glass bottle x 60 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Vitalink Health Products, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3563-01
May 28, 2030
BuroidIbuprofen
400 mg TabletBlister Pack of 10's (Box of 100's)
Rx
San Marino Laboratories CorporationPhilippines
—
DRP-3468
Jan 3, 2029
Dolan FPIbuprofen
100 mg / 5 mL SuspensionHDPE Bottle with Child Resistant Propylene Cap x 60 mL
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-13866
Dec 6, 2037
Dolan FP ForteIbuprofen
200 mg / 5 mL SuspensionHDPE Bottle with Child Resistant Propylene Cap x 60 mL (Box of 1's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-13865
Dec 7, 2037
DolexIbuprofen
100 mg/5 mL Oral SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's)
OTC
Yangzhou No. 3 Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY41508
Apr 17, 2028
DolexIbuprofen
100mg/5mL SuspensionPET Amber Bottle x 120mL (Box of 1's)
OTC
Yangzhou No. 3 Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY41395
Nov 22, 2027
DoupainIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-8817
Feb 9, 2037
FasgesicIbuprofen
400mg Soft-Gelatin CapsuleWhite Opaque PVC/Alu Blister Pack x 10's (Box of 10's)
OTC
Geltec Private LimitedIndia
Importer: Paradigm Pharma (Philippines) Corporation
DR-XY46714
Sep 19, 2029
FaspicIbuprofen (as L-arginine)
400 mg Film-Coated TabletAlu-Alu Blister Pack x 6's (Box of 30's)
Rx
Zambon S. p.AItaly
The Cathay Drug Co., Inc.
DR-XY32482
Aug 30, 2028
FenlexIbuprofen
200 mg / 5 mL SuspensionAmber Boston PP Bottle x 60 mL in a box
OTC
Square Pharmaceuticals, Inc.Philippines
Novomed Inc.
DRP-5227-02
Mar 19, 2027
FenlexIbuprofen
200 mg/5 mL SuspensionBoston Round PP Bottle x 60 mL (Box of 1's)
OTC
LifeSquare Laboratories, Inc.Philippines
Novomed Inc.
DRP-8624-2
Jan 15, 2030
FensydIbuprofen
200 mg Film-Coated TabletAlu/PVC Clear Blister Pack x 10's (Box of 100's)
OTC
Sydenham Laboratories, Inc.Philippines
—
DRP-10982
Dec 28, 2026
FeverfreeIbuprofen
100 mg/5 mL SuspensionAmber Bottle x 60 mL (Box of 1's)
Rx
The United Drug (1996) Co., Ltd.Thailand
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DR-XY39147
Mar 8, 2031
Fevral ForteIbuprofen
200 mg / 5 mL Oral SuspensionBoston Round Amber Bottle x 60 mL (Box of 1's)
OTC
Scheele Laboratories Phils., Inc.Philippines
—
DRP-8283
Jul 31, 2029
FinlaxIbuprofen
400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY30612
Mar 16, 2030
Gofen 400Ibuprofen
400 mg Softgel CapsuleAlu Blister Pack x 10's (Box of 60's)
Rx
Mega Lifesciences Public Company LimitedThailand
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.
DR-XY38708
Nov 2, 2031
Golfen 200Ibuprofen
Film-Coated Tablet ; 200mgAlu/PVC Film Clear Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: Golden Dale Pharma Corp.
DRP-9525
Feb 11, 2031
Golfen 400Ibuprofen
400 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's (Box of 10's,30's and 100's)
Rx
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp.
DRP-9526
Feb 11, 2031
IbuCareIbuprofen (Orange Flavor)
100 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Brigada Distributions, Inc.Trader: Solvang Pharmaceuticals, Inc.
DRP-3563-04
May 28, 2030
IbufenIbuprofen
400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-10724
Nov 15, 2031
Ibuglob-400Ibuprofen
400mg Film Coated TabletsAlu-PVC Blister Pack x 10's (Box of 100's)
OTC
Globela Pharma Private Limited.India
AMB HK Enterprises Inc.
DRP-14831
Jan 18, 2029
Ibuprowell 200Ibuprofen
200 mg Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Humanwell Puracap Pharmaceuticals (Wuhan) Co., Ltd.China
Sandoval Distributors, Inc.
DRP-13917
May 17, 2028
Ibuprozet 400Ibuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
OTC
Genom Biotech Pvt. Ltd.India
999-Seth Pharmaceutical Inc.Importer: Nelpa Lifesciences, Inc.
DRP-9710-01
Oct 23, 2030
IburaphIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Trader: St. Raphael Archangel Pharmaceutical Product Distribution
DRP-8816
Feb 11, 2037
IburosaIbuprofen
200 mg Softgel CapsuleAlu/PVC-PVDC Blister Pack x 10's (Box of 100's)
OTC
XL Laboratories Private LimitedIndia
Ambica International Corporation
DRP-18314
Jun 10, 2032
Ibusaph- ODIbuprofen
40 mg/mL Suspension (Oral Drops)PET Round Amber Bottle with Aluminum ROPP Cap x 15 m L and 30 m L with Plastic Dropper ( Box of 1 ' s)
OTC
Enicar Pharmaceuticals Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-9367
Dec 15, 2030
Ibusaph-100Ibuprofen
100 mg/5 mL SuspensionPET Round Amber Bottle with Aluminum ROPP Cap x 60 mL and 120 mL (Box of 1's)
OTC
Enicar Pharmaceuticals Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-9427
Oct 19, 2031
Ibusaph-200Ibuprofen
200 mg/5 mL SuspensionPET Round Amber Bottle with Aluminum ROPP Cap x 60 mL and 120 mL (Box of 1's)
OTC
Enicar Pharmaceuticals Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-9295
Oct 19, 2031
IbusoftIbuprofen
400mg Soft Gelatin CapsuleAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 50's and 100's)
OTC
Softech Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14669
Nov 29, 2028
Ibusoft 200Ibuprofen
200 mg Softgel CapsuleAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Humanwell Puracap Pharmaceuticals (Wuhan) Co., LtdChina
AMB HK Enterprises Inc.
DRP-9952
Apr 13, 2031
Ibusoft 400Ibuprofen
400 mg Softgel CapsuleAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Humanwell Puracap Pharmaceuticals (Wuhan) Co., LtdChina
AMB HK Enterprises Inc.
DRP-9953
Apr 13, 2031
IbuwellIbuprofen
200 mg TabletAlu/Clear PVC Blister Pack of 10's (Box of 100's)
OTC
S Kant Healthcare Ltd.India
Wellchem Pharmaceutical Products
DRP-17913
Apr 8, 2031
IbuwellIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
S Kant Healthcare Ltd.India
Wellchem Pharmaceutical Products
DRP-14867
Jan 25, 2029
Ibuzet 200Ibuprofen
200 mg/5 mL SuspensionPET Round Amber Bottle with White HDPE Cap x 60 mL and 120 mL (Box of 1's)
OTC
Enicar Pharmaceuticals Pvt. Ltd.India
777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-9295-03
Nov 23, 2030
ImuzenIbuprofen
200 mg/5 mL Suspension (Orange Flavor)Boston Round PP Bottle x 60 mL Box of 1's
OTC
Lifesquare Laboratories Inc.Philippines
—
DRP-8624
Jan 15, 2030
IntrafenIbuprofen
100 mg/mL (400 mg/4 mL) Solution for I.V. Infusion4 mL in 6 mL - capacity USP Type I clear and colorless glass vial sealed with grey butyl rubber stopper and blue aluminum flip-off seal (Box of 1's and Box of of 10's)
Rx
Gen İlaç ve Sağlık Ürünleri San. Ve Tic A.Ş.Turkey
Delex Pharma International, Inc.
DR-XY46120
Aug 24, 2029
IntrafenIbuprofen
100 mg/mL (800 mg/8 mL Solution for I. V. Infusion.8 mL in 10 mL capacity USP Type I clear and colorless glass vial sealed with grey butyl rubber stopper and blue aluminum flip-off seal (Box of 1's and Box of 10's)
Rx
Gen İlaç ve Sağlık Ürünleri San. Ve Tic A.Ş.Turkey
Delex Pharma International, Inc.
DR-XY46190
Aug 24, 2029
IprofenIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories IncPhilippines
—
DRP-8128
Mar 21, 2031
LaberfenIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 20's (Box of 100's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5635
Aug 19, 2028
Levifen 200Ibuprofen
200 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's, 30's and 100's (Box of 10's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: Docteur's Choice Corporation
DRP-9527
Feb 11, 2031
Levifen 400Ibuprofen
400 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's (Box of 10's,30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: Docteur's Choice Corporation
DRP-9528
Feb 11, 2031
MedbufenIbuprofen
100 mg/5 mL SuspensionAmber Glass Bottle x 60 mL; Amber Glass Bottle x 15 mL (Physician Sample)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma Inc.
DR-XY34725
Jul 17, 2028
MedicolIbuprofen
200 mg TabletAluminum Flex Foil x 10's (Box of 500's)
OTC
UNILAB, Inc.Philippines
—
DR-XY24958
Oct 22, 2029
Medicol AdvanceIbuprofen
200 mg Softgel CapsuleAlu PVC Blister pack x 5`s and 10`s (Box of 5's and 100's)
OTC
Belmont Softgel Pharma CorporationPhilippines
Trader: UNILAB, Inc.
DR-XY34641
Jun 6, 2032
Medicol AdvanceIbuprofen
200 mg Softgel CapsuleAlu/Clear PVC Blister Pack x 5's (Box of 5's); Alu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
PT. Darya-Varia Laboratoria Tbk.Indonesia
Unilab, Inc.
DR-XY46460
Mar 16, 2030
Medicol Advance 400Ibuprofen
400 mg Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Belmont Softgel Pharma CorporationPhilippines
Trader: UNILAB, Inc.
DR-XY41760
Jun 6, 2037
Medicol Advance 400Ibuprofen
400 mg Softgel CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
PT. Darya-Varia Laboratoria Tbk.Indonesia
Unilab, Inc.
DR-XY46461
Mar 16, 2030
Medicol I-400Ibuprofen
400 mg TabletAluminum Flex Foil x 4's (Box of 100's)
OTC
UNILAB, Inc.Philippines
—
DR-XY24952
Oct 21, 2029
MidolIbuprofen
200 mg TabletBlister Pack x 10’s (Box of 200’s and Box of 100’s (Box of 10’s x 10))
OTC
Swisspharma Research Laboratories, Inc.Philippines
Trader: A. Menarini Philippines, Inc.
DR-XY30477
Jan 17, 2030
MorexenIbuprofen
100 mg per 5 mL Suspension (Orange Flavor)Boston Round Amber Bottle with Metal Cap x 60 mL (Box of 1's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DRP-9627
Apr 13, 2031
MylanIbuprofen
200mg per 5mL Oral Suspension60 mL Amber Bottle per Box
Rx
New Myrex Laboratories, Inc.Philippines
Regimed Pharmaceutical Distributor
DRP-2840
Mar 16, 2031
MylanIbuprofen
200mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
OTC
Lumar Pharmaceutical Laboratory, Inc.Philippines
—
DR-XY43224
Feb 26, 2029
MylanIbuprofen
40mg/mL Suspension (Oral Drops)Amber Glass Bottle x 15mL (Box of 1's)
Rx
New Myrex Laboratories, Inc.Philippines
Regimed Pharmaceutical Distributor
DRP-5250
Aug 26, 2031
MyvilIbuprofen
100mg/5mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
OTC
New Myrex Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-1897
Oct 15, 2029
NanbuproIbuprofen
400 mg Film-Coated TabletAlu-PVC Blister Pack x 10’s (Box of 100’s)
OTC
Shandong Xinhua Pharmaceutical Co. Limited (Plant 206xy)China
Fosun Pharma (Philippines) Inc.
DRP-18143
May 13, 2031
New FevralIbuprofen
400 mg TabletAlu / PVC Blister Pack x 10's (Box of 100's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DRP-9550
Feb 18, 2031
New Fevral®Ibuprofen
200 mg TabletAlu / PVC Blister Pack of 10's (Box of 100's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DRP-9549
Feb 18, 2031
NoneIbuprofen
200 mg / 5 mL SuspensionAmber Boston PP Bottle x 60 mL Box of 1's
OTC
Square Pharmaceuticals, Inc.Philippines
—
DRP-5227
Mar 19, 2027
NoneIbuprofen
200 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DR-XY42955
Nov 15, 2028
NoneIbuprofen
200 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Incorporated
DRP-16776
Nov 15, 2028
NoneIbuprofen
200 mg CapsuleBlister Pack x 10's Box of 100's
OTC
Diamond Laboratories Inc.Philippines
—
DRP-7247
Oct 18, 2027
NoneIbuprofen
200 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
—
DRP-9464
Jan 12, 2031
NoneIbuprofen
400 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
—
DRP-9449
Jan 7, 2031
NoneIbuprofen
400 mg Softgel CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's and 30's)
Rx
Phil. United Pharma Corp.Philippines
—
DRP-9450
Jan 8, 2031
Pain GardIbuprofen
200 mg TabletAlu/Clear PVC Blister Pack x 20's Box of 100's
OTC
Diamond Laboratories, Inc.Philippines
Full Health International Pharma
DRP-6980
Apr 20, 2030
Pain GardIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
Diamond Laboratories Inc.Philippines
Full Health International Pharma
DRP-6986
Apr 20, 2030
PenfroIbuprofen
200 mg/5 mL SuspensionBoston Round PP Bottle x 60 mL (Box of 1's)
OTC
Lifesquare Laboratories, Inc.Philippines
Alman Pharmaceuticals, Inc.
DRP-8624-01
Jan 15, 2030
ProfenIbuprofen
100 mg/5 mL SuspensionAmber Glass Bottle x 120 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DR-XY36581
Sep 1, 2029
ProfenIbuprofen
200 mg/5 mL SuspensionAmber Glass Bottle x 120 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DR-XY36580
Sep 1, 2029
ProfenIbuprofen
200 mg/5 mL SuspensionAmber Glass Bottle x 120 mL (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-18246
Sep 1, 2029
PropainIbuprofen
400 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's)
OTC
BDA Healthcare Pvt. Ltd.India
Lealmeds Pharmaceuticals Inc.Trader: Pandix Healthcare LLP
DRP-16496
Apr 2, 2030
QuikgesicIbuprofen
400 mg Film-coated tabletAlu/PVC Blister Pack x 12's (Box of 12's)
OTC
Medreich Limited (Unit 3)India
Paradigm Pharma (Philippines) Corporation
DRP-17919
Apr 8, 2031
Rexprofen-200Ibuprofen
200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Next Wave (India)India
Aarex Pharma Distributor
DRP-11734
Apr 25, 2027
Rexprofen-400Ibuprofen
400 mg TabletAlu/ Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Next Wave (India)India
Aarex Pharma Distributor
DRP-11733
Apr 25, 2027
RheuxanIbuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-1942
Aug 5, 2029
Saphen-200Ibuprofen
200mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
OTC
Sapphire Lifesciences Pvt. Ltd.India
Importer: Nelpa Lifesciences, Inc.
DRP-11717
Apr 21, 2027
SAPHFEN-400Ibuprofen
400 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Sapphire Lifesciences Pvt. LtdIndia
Nelpa Lifesciences, Inc.
DRP-9710
May 11, 2031
Saphren 200Ibuprofen
200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's and 100's)
OTC
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-4296
Oct 23, 2030
Saphrofen-100Ibuprofen
Suspension 100 mg/5 mLPET Round Amber Bottle with White HDPE Cap x 60 mL and 120 mL (Box of 1's)
Rx
Azine Healthcare Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd
DRP-9369
Dec 15, 2030
Saphrofen-200Ibuprofen
200 mg/5 mL SuspensionPET Round Amber Bottle with White HDPE Cap x 60 mL and 120 mL (Box of 1's)
Rx
Azine Healthcare Pvt. Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd
DRP-9308
Nov 23, 2030
Saphrofen-ODIbuprofen
40 mg/mL Suspension (Oral Drops)PET Round Amber Bottle with White HDPE Cap x 15 mL and 30 mL with Plastic Dropper (Box of 1's)
Rx
Sapphire Lifesciences Pvt. Ltd.India
Importer: Nelpa Lifesciences, Inc.
DRP-9426
Jan 7, 2031
SqfenIbuprofen
200 mg / 5 mL SuspensionAmber Boston PP Bottle x 60 mL in a box
OTC
Square Pharmaceuticals, Inc.Philippines
Alman Pharmaceuticals, Inc.
DRP-5227-01
Mar 19, 2027
SqfenIbuprofen
200 mg/5 mL Suspension (Orange Flavor)Boston Round PP Bottle x 60 mL (Box of 1's)
OTC
Lifesquare Laboratories, Inc.Philippines
Alman Pharmaceuticals, Inc.
DRP-8624-03
Jan 15, 2030
UnbrandedIbuprofen
200 mg CapsuleBlister Pack x 10's (Box of 100's)
OTC
Interchemex Laboratories, Inc.Philippines
—
DR-XY46604
Jun 4, 2036
UnbrandedIbuprofen
200 mg TabletAlu / PVC Blister Pack of 10's (Box of 100's)
OTC
Scheele Laboratories Phils., Inc.Philippines
RiteMED Phils., Inc.
DRP-9549-01
Jan 23, 2032
UnbrandedIbuprofen
400 mg Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Softgel Healthcare Pvt. Ltd.India
Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd.
DR-XY48952
Dec 21, 2030
(no brand name)Ibuprofen
200 mg Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Phil Inter Pharma Co., Ltd.Vietnam
RiteMED Phils., Inc.
DR-XY45438
Oct 10, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.

The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate.

Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.

Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.

The concurrent use of aspirin and an NSAID, such as ibuprofen, increases the risk of serious gastrointestinal (GI) events [see WARNINGS]. Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.

NSAIDs are contraindicated in the setting of CABG [see CONTRAINDICATIONS]. Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment.

In this same cohort, the incidence of death in the first year post MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of ibuprofen tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ibuprofen tablets are used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Hypertension NSAIDs including ibuprofen tablets can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events.

Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ibuprofen tablets should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

Heart Failure and Edema The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of Ibuprofen may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] [see DRUG INTERACTIONS]. Avoid the use of ibuprofen tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.

If ibuprofen tablets are used in patients with severe heart failure, monitor patients for signs of worsening heart failure. Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation NSAIDs, including ibuprofen tablets can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal.

These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year.

These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding.

Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status.

Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. To minimize the potential risk for an adverse GI event in patients treated with a NSAID, the lowest effective dose should be used for the shortest possible duration.

Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

Renal Effects Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Advanced Renal Disease No information is available from controlled clinical studies regarding the use of ibuprofen tablets in patients with advanced renal disease.

Therefore, treatment with ibuprofen tablets is not recommended in these patients with advanced renal disease. If ibuprofen tablets therapy must be initiated, close monitoring of the patients renal function is advisable. Anaphylactoid Reactions As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ibuprofen tablets.

Ibuprofen tablets should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs [see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma].

Emergency help should be sought in cases where an anaphylactoid reaction occurs. Serious Skin Reactions NSAIDs, including ibuprofen tablets can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE).

FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of ibuprofen tablets at the first appearance of skin rash or any other sign of hypersensitivity.

Ibuprofen tablets are contraindicated in patients with previous serious skin reactions to NSAIDs [see CONTRAINDICATIONS]. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ibuprofen tablets. Some of these events have been fatal or life-threatening.

DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present.

Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ibuprofen tablets and evaluate the patient immediately.

Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs, including ibuprofen tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including ibuprofen tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs, including ibuprofen tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.

These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation.

In some post-marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ibuprofen tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ibuprofen tablets treatment extends beyond 48 hours.

Discontinue ibuprofen tablets if oligohydramnios occurs and follow up according to clinical practice [see PRECAUTIONS, Pregnancy].

Drug interactions

Drug or classSeverityEffectWhat to do
ACE inhibitors, ARBs, diuretics ("triple whammy")Adjust or monitorLess blood-pressure and diuretic effect; risk of acute kidney injury (label); hyperkalemia, especially in older, volume-depleted or CKD patients (NSAID class labeling).Avoid the triple combination where possible; if used, check creatinine and potassium within 1 to 2 weeks and keep the patient hydrated.
Anticoagulants (warfarin), aspirin; SSRIs, SNRIsAdjust or monitorHigher risk of serious bleeding (label: warfarin, aspirin; SSRIs and SNRIs: NSAID class labeling).Avoid if possible; otherwise monitor for bleeding.
Other NSAIDs or salicylatesAvoidMore gastrointestinal toxicity without added benefit (label).Do not combine.
Lithium, methotrexateAdjust or monitorHigher lithium or methotrexate levels (label).Monitor drug levels and kidney function.
Cyclosporine, digoxinAdjust or monitorMore nephrotoxicity with cyclosporine; higher digoxin levels (NSAID class labeling).Monitor creatinine and digoxin levels.
Low-dose aspirin (cardioprotection)Adjust or monitorIbuprofen can block aspirin's antiplatelet effect (label).Give immediate-release low-dose aspirin at least 2 hours before once-daily ibuprofen; not shown for enteric-coated aspirin (label).

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

Drug Interactions ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin Pharmacodynamic studies have demonstrated interference with the antiplatelet activity of aspirin when ibuprofen 400 mg, given three times daily, is administered with enteric-coated low-dose aspirin.

The interaction exists even following a once-daily regimen of ibuprofen 400 mg, particularly when ibuprofen is dosed prior to aspirin. The interaction is alleviated if immediate-release low-dose aspirin is dosed at least 2 hours prior to a once-daily regimen of ibuprofen; however, this finding cannot be extended to enteric-coated low-dose aspirin [see CLINICAL PHARMACOLOGY, Pharmacodynamics].

Because there may be an increased risk of cardiovascular events due to the interference of ibuprofen with the antiplatelet effect of aspirin, for patients taking low-dose aspirin for cardioprotection who require analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics, where appropriate. When ibuprofen tablets are administered with aspirin, its protein binding is reduced, although the clearance of free ibuprofen tablets is not altered.

The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ibuprofen and aspirin is not generally recommended because of the potential for increased adverse effects. Diuretics Clinical studies, as well as post-marketing observations, have shown that ibuprofen tablets can reduce the natriuretic effect of furosemide and thiazides in some patients.

This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure [see WARNINGS, Renal Effects], as well as to assure diuretic efficacy. Lithium Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.

The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration. This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

(Read circulars for lithium preparation before use of such concurrent therapy.) Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.

Warfarin-type anticoagulants Several short-term controlled studies failed to show that ibuprofen tablets significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants. However, because bleeding has been reported when ibuprofen tablets and other NSAIDs have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen tablets to patients on anticoagulants.

The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. H-2 Antagonists In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.

Adverse reactions

Common

  • Gastrointestinal complaints (4% to 16% in trials), e.g., nausea, epigastric pain, heartburn

Serious

  • Cardiovascular thrombotic events (boxed warning)
  • Gastrointestinal bleeding, ulceration, perforation (boxed warning)
  • Acute kidney injury, papillary necrosis; hyperkalemia (NSAID class labeling)
  • Heart failure and edema; hypertension
  • Hepatotoxicity
  • Serious skin reactions, DRESS, anaphylaxis
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The most frequent type of adverse reaction occurring with ibuprofen tablets is gastrointestinal. In controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%. In controlled studies when ibuprofen tablets were compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin- or indomethacin-treated patients.

Adverse reactions observed during controlled clinical trials at an incidence greater than 1% are listed in the table. Those reactions listed in Column one encompass observations in approximately 3,000 patients. More than 500 of these patients were treated for periods of at least 54 weeks. Still other reactions occurring less frequently than 1 in 100 were reported in controlled clinical trials and from marketing experience.

These reactions have been divided into two categories: Column two of the table lists reactions with therapy with ibuprofen tablets where the probability of a causal relationship exists: for the reactions in Column three, a causal relationship with ibuprofen tablets has not been established. Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 mg or less per day in clinical trials of patients with rheumatoid arthritis.

The increases in incidence were slight and still within the ranges reported in the table. Incidence Greater Than 1% (but less than 3%) Probable Causal Relationship Precise Incidence Unknown (but less than 1%) Probable Causal Relationship** Precise Incidence Unknown (but less than 1%) Causal Relationship Unknown** GASTROINTESTINAL Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of Gl tract (bloating and flatulence) Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; pancreatitis CENTRAL NERVOUS SYSTEM Dizziness*, headache, nervousness Depression, insomnia, confusion, emotional liability, somnolence, aseptic meningitis with fever and coma [see PRECAUTIONS] Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri DERMATOLOGIC Rash* (including maculopapular type), pruritus Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia Toxic epidermal necrolysis, photoallergic skin reactions SPECIAL SENSES Tinnitus Hearing loss, amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) [see PRECAUTIONS] Conjunctivitis, diplopia, optic neuritis, cataracts HEMATOLOGIC Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit [see PRECAUTIONS] Bleeding episodes (e.g., epistaxis, menorrhagia) METABOLIC/ENDOCRINE Decreased appetite Gynecomastia, hypoglycemic reaction, acidosis CARDIOVASCULAR Edema, fluid retention (generally responds promptly to drug discontinuation) [see PRECAUTIONS] Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitations Arrhythmias (sinus tachycardia, sinus bradycardia) ALLERGIC Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm [see CONTRAINDICATIONS] Serum sickness, lupus erythematosus syndrome, Henoch-Schonlein vasculitis, angioedema RENAL Acute renal failure [see PRECAUTIONS], decreased creatinine clearance, polyuria, azotemia, cystitis, hematuria Renal papillary necrosis MISCELLANEOUS Dry eyes and mouth, gingival ulcer, rhinitis tests * Reactions occurring in 3% to 9% of patients treated with ibuprofen tablets.

(Those reactions occurring in less than 3% of the patients are unmarked.) ** Reactions are classified under “Probable Causal Relationship (PCR)” if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under “Causal Relationship Unknown” if seven or more events have been reported but the criteria for PCR have not been met.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Post-marketing Experience The following adverse reactions have been identified during postapproval use of ibuprofen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and Appendages: Exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and fixed drug eruption (FDE).

Adverse reaction frequency tables (US label) US FDA label
Incidence Greater Than 1%(but less than 3%)Probable Causal RelationshipPrecise Incidence Unknown(but less than 1%)Probable Causal Relationship**Precise Incidence Unknown(but less than 1%)Causal Relationship Unknown**
GASTROINTESTINALNausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of Gl tract (bloating and flatulence)Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; pancreatitis
CENTRAL NERVOUS SYSTEMDizziness*, headache, nervousnessDepression, insomnia, confusion, emotional liability, somnolence, aseptic meningitis with fever and coma [see PRECAUTIONS]Paresthesias, hallucinations, dream abnormalities, pseudotumor cerebri
DERMATOLOGICRash* (including maculopapular type), pruritusVesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopeciaToxic epidermal necrolysis, photoallergic skin reactions
SPECIAL SENSESTinnitusHearing loss, amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) [see PRECAUTIONS]Conjunctivitis, diplopia, optic neuritis, cataracts
HEMATOLOGICNeutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit [see PRECAUTIONS]Bleeding episodes (e.g., epistaxis, menorrhagia)
METABOLIC/ENDOCRINEDecreased appetiteGynecomastia, hypoglycemic reaction, acidosis
CARDIOVASCULAREdema, fluid retention (generally responds promptly to drug discontinuation) [see PRECAUTIONS]Congestive heart failure in patients with marginal cardiac function, elevated blood pressure, palpitationsArrhythmias (sinus tachycardia, sinus bradycardia)
ALLERGICSyndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm [see CONTRAINDICATIONS]Serum sickness, lupus erythematosus syndrome, Henoch-Schonlein vasculitis, angioedema
RENALAcute renal failure [see PRECAUTIONS], decreased creatinine clearance, polyuria, azotemia, cystitis, hematuriaRenal papillary necrosis
MISCELLANEOUSDry eyes and mouth, gingival ulcer, rhinitis tests
* Reactions occurring in 3% to 9% of patients treated with ibuprofen tablets. (Those reactions occurring in less than 3% of the patients are unmarked.)** Reactions are classified under “Probable Causal Relationship (PCR)” if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under “Causal Relationship Unknown” if seven or more events have been reported but the criteria for PCR have not been met.

Monitoring parameters

  • Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, older adults, or with diuretics, ACE inhibitors or ARBs. Gastrointestinal bleeding; hemoglobin with long-term use. Kidney
  • Serum creatinine and potassium at baseline and during use in CKD, heart failure, cirrhosis, older adults, or with ACE inhibitors, ARBs or diuretics
  • Blood pressure; signs of gastrointestinal bleeding; hemoglobin if anemia symptoms
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Risk Summary Use of NSAIDs, including ibuprofen tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of ibuprofen tablets use between about 20 and 30 weeks of gestation, and avoid ibuprofen tablets use at about 30 weeks of gestation and later in pregnancy [see WARNINGS, Fetal Toxicity].

Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including ibuprofen tablets, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.

Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response.

Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development.

In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization.

In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including ibuprofen tablets, can cause premature closure of the fetal ductus arteriosus [see WARNINGS, Fetal Toxicity]. Oligohydramnios/Neonatal Renal Impairment If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible.

If ibuprofen tablets treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue ibuprofen tablets and follow up according to clinical practice [see WARNINGS, Fetal Toxicity]. Data Human Data There are no adequate, well-controlled studies in pregnant women.

Ibuprofen tablets should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Premature Closure of Fetal Ductus Arteriosus: Published literature reports that the use of NSAIDs at about 30 weeks of gestation and later in pregnancy may cause premature closure of the fetal ductus arteriosus.

Oligohydramnios/Neonatal Renal Impairment: Published studies and post-marketing reports describe maternal NSAID use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

In many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug. There have been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. Some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis.

Methodological limitations of these post-marketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use.

Because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to NSAIDs through maternal use is uncertain. Labor and Delivery In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred.

The effects of ibuprofen tablets on labor and delivery in pregnant women are unknown.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ibuprofen tablets, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pharmacokinetics

Key PK parameters

Time to peak1 to 2 hours
Half-life1.8 to 2 hours
Metabolism (CYP, transporters)Hepatic oxidation to inactive metabolites A and B
Active metabolitesNone
Renal excretion kidney45% to 79% of dose in urine within 24 hours (metabolites); about 1% free drug
Dialyzability kidneyNot stated
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Ibuprofen is rapidly metabolized and eliminated in the urine.

The excretion of ibuprofen is virtually complete 24 hours after the last dose.

The serum half-life is 1.8 to 2.0 hours.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Ibuprofen tablets contain ibuprofen which possesses analgesic and antipyretic activities. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition. In clinical studies in patients with rheumatoid arthritis and osteoarthritis, ibuprofen tablets have been shown to be comparable to aspirin in controlling pain and inflammation and to be associated with a statistically significant reduction in the milder gastrointestinal side effects [see ADVERSE REACTIONS].

Ibuprofen tablets may be well tolerated in some patients who have had gastrointestinal side effects with aspirin, but these patients when treated with ibuprofen tablets should be carefully followed for signs and symptoms of gastrointestinal ulceration and bleeding. Although it is not definitely known whether ibuprofen tablets causes less peptic ulceration than aspirin, in one study involving 885 patients with rheumatoid arthritis treated for up to one year, there were no reports of gastric ulceration with ibuprofen tablets whereas frank ulceration was reported in 13 patients in the aspirin group (statistically significant p < 0.001).

Gastroscopic studies at varying doses show an increased tendency toward gastric irritation at higher doses. However, at comparable doses, gastric irritation is approximately half that seen with aspirin. Studies using 51 Cr-tagged red cells indicate that fecal blood loss associated with ibuprofen tablets in doses up to 2400 mg daily did not exceed the normal range, and was significantly less than that seen in aspirin-treated patients.

In clinical studies in patients with rheumatoid arthritis, ibuprofen tablets have been shown to be comparable to indomethacin in controlling the signs and symptoms of disease activity and to be associated with a statistically significant reduction of the milder gastrointestinal [see ADVERSE REACTIONS] and CNS side effects. Ibuprofen tablets may be used in combination with gold salts and/or corticosteroids.

Controlled studies have demonstrated that ibuprofen tablets are a more effective analgesic than propoxyphene for the relief of episiotomy pain, pain following dental extraction procedures, and for the relief of the symptoms of primary dysmenorrhea. In patients with primary dysmenorrhea, ibuprofen tablets have been shown to reduce elevated levels of prostaglandin activity in the menstrual fluid and to reduce resting and active intrauterine pressure, as well as the frequency of uterine contractions.

The probable mechanism of action is to inhibit prostaglandin synthesis rather than simply to provide analgesia. Pharmacodynamics In a healthy volunteer study, ibuprofen 400 mg given once daily, administered 2 hours prior to immediate-release aspirin (81 mg) for 6 days, showed an interaction with the antiplatelet activity of aspirin as measured by % serum thromboxane B2 (TxB2) inhibition at 24 hours following the day-6 aspirin dose [53%].

An interaction was still observed, but minimized, when ibuprofen 400 mg given once-daily was administered as early as 8 hours prior to the immediate-release aspirin dose [90.7%]. However, there was no interaction with the antiplatelet activity of aspirin when ibuprofen 400 mg, given once daily, was administered 2 hours after (but not concomitantly, 15 min, or 30 min after) the immediate-release aspirin dose [99.2%].

In another study, where immediate-release aspirin 81 mg was administered once daily with ibuprofen 400 mg given three times daily (1, 7, and 13 hours post-aspirin dose) for 10 consecutive days, the mean % serum thromboxane B2 (TxB2) inhibition suggested no interaction with the antiplatelet activity of aspirin [98.3%]. However, there were individual subjects with serum TxB2 inhibition below 95%, with the lowest being 90.2%.

When a similarly designed study was conducted with enteric-coated aspirin, where healthy subjects were administered enteric-coated aspirin 81 mg once daily for 6 days and ibuprofen 400 mg three times daily (2, 7 and 12 h post-aspirin dose) for 6 days, there was an interaction with the antiplatelet activity at 24 hours following the day-6 aspirin dose [67%] [see PRECAUTIONS, Drug Interactions]. Pharmacokinetics The ibuprofen in ibuprofen tablets is rapidly absorbed.

Peak serum ibuprofen levels are generally attained one to two hours after administration. With single doses up to 800 mg, a linear relationship exists between amount of drug administered and the integrated area under the serum drug concentration vs time curve. Above 800 mg, however, the area under the curve increases less than proportional to increases in dose.

There is no evidence of drug accumulation or enzyme induction. The administration of ibuprofen tablets either under fasting conditions or immediately before meals yields quite similar serum ibuprofen concentration-time profiles. When ibuprofen tablets are administered immediately after a meal, there is a reduction in the rate of absorption but no appreciable decrease in the extent of absorption.

The bioavailability of the drug is minimally altered by the presence of food. A bioavailability study has shown that there was no interference with the absorption of ibuprofen when ibuprofen tablets were given in conjunction with an antacid containing both aluminum hydroxide and magnesium hydroxide. Ibuprofen is rapidly metabolized and eliminated in the urine.

The excretion of ibuprofen is virtually complete 24 hours after the last dose. The serum half-life is 1.8 to 2.0 hours. Studies have shown that following ingestion of the drug, 45% to 79% of the dose was recovered in the urine within 24 hours as metabolite A (25%), (+)-2-[p -(2hydroxymethyl-propyl) phenyl] propionic acid and metabolite B (37%), (+)-2-[p -(2carboxypropyl)phenyl] propionic acid; the percentages of free and conjugated ibuprofen were approximately 1% and 14%, respectively.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ibuprofen 100 mg/5 mL, 60 mL Bottle₱24.89–₱58.32Reference ₱37.76per bottleDPRI procurement range
Ibuprofen 200 mg Tablet₱0.88–₱1.75Reference ₱0.94per tabletDPRI procurement range
Ibuprofen 200 mg/5 mL, 60 mL Bottle₱49.00–₱87.50Reference ₱68.74per bottleDPRI procurement range
Ibuprofen 400 mg Tablet₱0.85–₱2.15Reference ₱0.98per tabletDPRI procurement range
100 mg/5 mL syrup/suspension in 60 mL₱67.75per unitPhilHealth GAMOT fixed fee
200 mg tablet₱5.00per tabletPhilHealth GAMOT fixed fee
200 mg/5 mL syrup/suspension in 60 mL₱103.75per unitPhilHealth GAMOT fixed fee
400 mg tablet₱8.75per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ibuprofen
PNF listingOral: 200 mg and 400 mg tablet
PNF listingOral: 100 mg/5 mL, 60 mL syrup/suspension
PNF listingOral: 200 mg/5 mL, 60 mL suspension
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Ibuprofen · Amneal Pharmaceuticals LLC [US FDA-approved label, version 11, July 29, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17577b3b-e755-45d1-8b53-775d058578b2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  7. Amneal Pharmaceuticals LLC. (2026). Ibuprofen tablets [Prescribing information; US FDA-approved label, ANDA078558, set ID 17577b3b-e755-45d1-8b53-775d058578b2, version effective July 29, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17577b3b-e755-45d1-8b53-775d058578b2
  8. Misurac, J. M., Knoderer, C. A., Leiser, J. D., Nailescu, C., Wilson, A. C., & Andreoli, S. P. (2013). Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. The Journal of Pediatrics, 162(6), 1153–1159.e1. https://doi.org/10.1016/j.jpeds.2012.11.069
  9. Zameer Pharmaceuticals LLC. (2025). Naproxen tablets [Prescribing information; US FDA-approved label, set ID d2e5553a-7c90-407c-9f07-3be65560c23a] (NSAID class labeling, section 7). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2e5553a-7c90-407c-9f07-3be65560c23a

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .